Department of Neurosurgery, Hospital Geral de Fortaleza, Fortaleza-CE, Brazil.
Department of Neurosurgery, Universidade Estadual de Campinas, Campinas-SP, Brazil.
World Neurosurg. 2014 Jul-Aug;82(1-2):e281-90. doi: 10.1016/j.wneu.2013.08.028. Epub 2013 Aug 29.
To present our experience with the surgical management of giant pituitary adenomas in a series of 50 cases operated on by an endoscopic endonasal approach.
A retrospective data analysis of all patients who underwent transsphenoidal endonasal endoscopic surgery at the General Hospital of Fortaleza, Brazil, between January 1998 and November 2011 was performed. Patients who presented with pituitary adenomas larger than 4 cm were included in the study. Analysis of factors related to the choice of the operative approach, hormonal and visual status, extent of resection, tumor control rates, clinical outcome, and complications were evaluated.
Fifty cases (10.41%) matched our inclusion criteria. Nonfunctioning tumors were present in 42 patients (84%); among functioning adenomas, five patients (10%) had growth hormone-secreting adenomas, and three patients (6%) had prolactinomas. Total removal of the tumor occurred in 19 cases (38%), near-total removal in 9 cases (18%), and partial removal in 22 cases (44%). Postoperative cerebrospinal fluid leaks occurred in four cases (8%). Postoperative diabetes insipidus was present in 10% and new anterior pituitary insufficiency affecting one axis or more than one axis was observed in 22% and 14%, respectively. The presence of Knosp score ≥3 was associated with subtotal resection. Patients harboring hormonally active adenomas were submitted to adjuvant medical therapy for long-term clinical control. Vision improved in 38 patients (76%), with only one case of visual deterioration reported.
Transsphenoidal endoscopic endonasal surgery may provide effective treatment for patients with giant adenomas when performed by a surgical team that specializes in pituitary surgery. In cases in which total resection by the endoscopic approach may be associated with important complications, we advocate the use of partial resections followed by adjuvant drug therapy or radiotherapy. In cases of progressive enlargement of residual lesions, a second endoscopic debulking of the tumor may be considered for control of the disease.
介绍我们采用经鼻内镜手术治疗 50 例大型垂体腺瘤的经验。
对巴西福塔雷萨总医院 1998 年 1 月至 2011 年 11 月期间采用经蝶窦内镜手术治疗的所有患者进行回顾性数据分析。研究纳入肿瘤最大径大于 4cm 的患者。分析与手术入路选择、激素和视觉状态、肿瘤切除程度、肿瘤控制率、临床转归和并发症相关的因素。
50 例(10.41%)符合纳入标准。42 例(84%)为无功能腺瘤,其中 5 例(10%)为生长激素腺瘤,3 例(6%)为催乳素腺瘤。肿瘤全切除 19 例(38%),近全切除 9 例(18%),部分切除 22 例(44%)。术后发生 4 例(8%)脑脊液漏。术后发生尿崩症 10%,新发单一或多垂体轴功能不足分别为 22%和 14%。Knosp 分级≥3 与次全切除相关。功能性腺瘤患者行辅助药物治疗以长期控制临床症状。38 例(76%)视力改善,仅 1 例视力恶化。
经蝶窦内镜手术可作为一种有效的治疗方法,适用于由擅长垂体手术的外科医生团队治疗大型腺瘤患者。对于内镜全切除可能与严重并发症相关的病例,我们提倡采用部分切除,随后进行辅助药物或放疗。对于残留病变进展的病例,可考虑再次内镜肿瘤减容术以控制疾病。